Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections Overview | 6 | 1 |
| Therapeutics Development | 7 | 2 |
| Pipeline Products for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections Overview | 7 | 1 |
| Pipeline Products for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections Comparative Analysis | 8 | 1 |
| Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections Therapeutics under Development by Companies | 9 | 1 |
| Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections Therapeutics under Investigation by Universities/Institutes | 10 | 1 |
| Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections Pipeline Products Glance | 11 | 2 |
| Clinical Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections Products under Development by Companies | 13 | 1 |
| Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections Products under Investigation by Universities/Institutes | 14 | 1 |
| Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections Companies Involved in Therapeutics Development | 15 | 5 |
| Destiny Pharma Limited | 15 | 1 |
| Galapagos NV | 16 | 1 |
| MGB Biopharma Limited | 17 | 1 |
| Syntiron LLC | 18 | 1 |
| Techulon, Inc. | 19 | 1 |
| Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections Therapeutics Assessment | 20 | 9 |
| Assessment by Monotherapy Products | 20 | 1 |
| Assessment by Target | 21 | 2 |
| Assessment by Mechanism of Action | 23 | 2 |
| Assessment by Route of Administration | 25 | 2 |
| Assessment by Molecule Type | 27 | 2 |
| Drug Profiles | 29 | 11 |
| acALY-18 - Drug Profile | 29 | 1 |
| Product Description | 29 | 1 |
| Mechanism of Action | 29 | 1 |
| R&D Progress | 29 | 1 |
| Antisense Oligonucleotide for Hospital Acquired MRSA - Drug Profile | 30 | 1 |
| Product Description | 30 | 1 |
| Mechanism of Action | 30 | 1 |
| R&D Progress | 30 | 1 |
| exeporfinium chloride - Drug Profile | 31 | 1 |
| Product Description | 31 | 1 |
| Mechanism of Action | 31 | 1 |
| R&D Progress | 31 | 2 |
| GLPG-1492 - Drug Profile | 33 | 1 |
| Product Description | 33 | 1 |
| Mechanism of Action | 33 | 1 |
| R&D Progress | 33 | 1 |
| MGBBP-3 - Drug Profile | 34 | 1 |
| Product Description | 34 | 1 |
| Mechanism of Action | 34 | 1 |
| R&D Progress | 34 | 2 |
| MH-003 - Drug Profile | 36 | 1 |
| Product Description | 36 | 1 |
| Mechanism of Action | 36 | 1 |
| R&D Progress | 36 | 1 |
| Peptides to Disrupt Cell Membrane for Infectious Diseases - Drug Profile | 37 | 1 |
| Product Description | 37 | 1 |
| Mechanism of Action | 37 | 1 |
| R&D Progress | 37 | 1 |
| Siderocillin - Drug Profile | 38 | 1 |
| Product Description | 38 | 1 |
| Mechanism of Action | 38 | 1 |
| R&D Progress | 38 | 1 |
| Staphylococcus aureus vaccine - Drug Profile | 39 | 1 |
| Product Description | 39 | 1 |
| Mechanism of Action | 39 | 1 |
| R&D Progress | 39 | 1 |
| Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections Recent Pipeline Updates | 40 | 2 |
| Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Dormant Projects | 42 | 1 |
| Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections Discontinued Products | 43 | 1 |
| Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections Product Development Milestones | 44 | 1 |
| Featured News &Press Releases | 44 | 1 |
| Jun 02, 2015: MGB Biopharma Succeeds in Developing an IV Formulation of MGB-BP-3 for the Treatment of Systemic Susceptible and Resistant Gram-Positive Hospital-Acquired Infections | 44 | 1 |
| Appendix | 45 | 2 |
| Methodology | 45 | 1 |
| Coverage | 45 | 1 |
| Secondary Research | 45 | 1 |
| Primary Research | 45 | 1 |
| Expert Panel Validation | 45 | 1 |
| Contact Us | 45 | 1 |
| Disclaimer | 46 | 1 |